Is RAPT Therapeutics Inc (RAPT) overvalued? · $132.1M cap
RAPT Therapeutics Inc (RAPT) is a biotechnology company listed on US.
This page asks whether RAPT Therapeutics Inc (RAPT) looks expensive on cached numbers — not a short thesis.
Latest reported RAPT revenue for 2023-12-31 was $0. Net income was -$116.8M. Revenue was down 100.0% from 2022-12-31 to 2023-12-31. RAPT currently screens at market cap $132.1M.
RAPT currently screens at market cap $132.1M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next RAPT 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the RAPT stock page for the full model, not this heading.
Not investment advice.